XTalks

FEBRUARY 5, 2024

Why it did so well: Darzalex was the first human anti-CD38 monoclonal antibody approved by the FDA for multiple myeloma. Despite Bristol Myers Squibb’s Revlimid remaining the top-selling drug for multiple myeloma for several years now, Darzalex is not too far behind. The worldwide net trade sales of Darzalex were $2.26

FDA Approval 101

FDA Approval Drugs Sales Development 101

The Pharma Data

MAY 7, 2021

EU regulator begins real-time review of GSK-Vir COVID-19 antibody drug ( Reuters ) ( Press ). Catalent snaps up Promethera’s cell therapy subsidiary, complete with a Belgian plant to help scale plasmid DNA efforts ( Endpoints ). Generic Drug Cos. Pharma & Biotech.

Vaccination 52

Vaccination Vaccine Drugs Regulation 52

XTalks

FEBRUARY 5, 2024

Why it did so well: Darzalex was the first human anti-CD38 monoclonal antibody approved by the FDA for multiple myeloma. Despite Bristol Myers Squibb’s Revlimid remaining the top-selling drug for multiple myeloma for several years now, Darzalex is not too far behind. The worldwide net trade sales of Darzalex were $2.26

FDA Approval 52

FDA Approval Drugs Sales Development 52

XTalks

AUGUST 2, 2023

2) Darzalex (daratumumab) Darzalex is a targeted monoclonal antibody that slows or stops the progression of multiple myeloma (a blood cancer) by binding to the CD38 protein on multiple myeloma cells. The monoclonal antibody targets CD20, a protein found on the surface of B lymphocytes (B cells). billion in 2022, a 32.44

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

SEPTEMBER 14, 2020

Moderna, for one, recently reported positive results in older adults between 56 and 71, as well as those 71 years of age and older, who reportedly mounted levels of neutralizing antibodies against the SARS-CoV-2 virus after two doses of its vaccine that were comparable to those seen in younger adults. Johnson & Johnson’s COVID-19 Vaccine.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92